During the second half of FY26, PayU India also exited certain "negative margin portfolios", impacting its sequential revenue growth. In th...

Indian markets showed volatility, ending nearly flat despite positive signals. Analysts note Nifty faces resistance from key moving average...

A product marketing manager's resignation took an unexpected turn when his company offered a significant salary hike just days before his d...

Indian pharmaceutical MSMEs are facing immense pressure from rising costs, supply chain woes, and stringent regulations. Industry represent...

Indian markets are showing signs of recovery as geopolitical tensions ease, paving the way for a stronger earnings outlook in the second ha...

Laurus Labs' stock has surged 30% on robust FY26 results, fueled by a booming contract manufacturing business and improved product mix. The...

Indian contract manufacturers are poised for significant growth as global pharmaceutical giants diversify away from China. Companies like S...

Wimbledon's top tennis stars are continuing their protest over prize money by cutting media time to just 15 minutes per match during the fi...

Indian stock markets are defying foreign investor caution, driven by resilient June-quarter earnings. Companies are navigating geopolitical...

Mamaearth's parent company, Honasa Consumer, is acquiring a majority stake in nutraceuticals brand Fluence Pharma for ₹135 crore. This stra...

Honasa Consumer has secured a majority stake in Mumbai's hair therapy brand Fluence Pharma for Rs 135 crore. This move marks the company's ...

Honasa Consumer, parent of Mamaearth, is acquiring a 58% stake in nutraceuticals firm Fluence Pharma for Rs 135 crore, marking its entry in...

Healthium Medtech's CEO Anish Bafna is transitioning to non-executive chairman as KKR-owned company seeks a new chief within a month. Bafna...

India's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...

Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US...

Aurobindo Pharma's US arm has secured Federal Trade Commission approval for its $250 million acquisition of Lannett Company. This strategic...

India's largest drugmaker, Sun Pharma, is set to acquire Mumbai-based Innovcare Lifesciences for approximately $28.7 million in an all-cash...